



AN INTEGRATIVE STRATEGY OF TESTING SYSTEMS FOR IDENTIFICATION OF ENDOCRINE DISRUPTERS RELATED TO METABOLIC DISORDERS

11
PARTNERS

5
EUROPEAN COUNTRIES

5
YEARS PROJECT
2019 → 2023

8
WORK PACKAGES

6,7 millions €
BUDGET

1
SME




CONTEXT

Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union to reduce the levels of endocrine disruptors (EDs) for consumers, new and effective methods for ED testing are needed.



OBJECTIVES

The OBERON project aims to establish an integrated testing strategy (ITS) to detect endocrine disruptors-related metabolic disorders by developing, improving and validating a battery of test systems. It will be based on the concept of an integrated approach for testing and assessment (IATA).



This project has received funding from the European Union's Horizon 2020 Research and Innovation programme under Grant Agreement N° 825712.





EXPECTED RESULTS

- To set up and make available an innovative battery of new, easy to use, effective and validated test systems.
- To propose a decision tree based on a tiered integrated approach for testing and assessment (IATA) that support reduction of the use of animal testing in industries and regulatory agencies.
- To improve mechanistic knowledge on EDs based on data generated by OBERON and to integrate them into AOPs with the aim to improve risk assessment frameworks for human health effects.
- To provide putative effect markers for metabolic disorders



PARTNERS & CLUSTER

FRANCE



SPAIN



ITALIA



CZECH REPUBLIC



GREECE



Participation in the European cluster



SC1-BHC-27-2018

CONTACT US

COORDINATOR

Ass. Prof. Karine **AUDOUZE**
 Université de Paris, Inserm U1124
 karine.audouze@inserm.fr

SCIENTIFIC MANAGER

Céline **DESSEILLE**
 celine.desseille@inserm.fr

PROJECT MANAGER

Marie **HAUDUROY**
 marie.hauduroy@inserm-transfert.fr

SENIOR PROJECT MANAGER

Delphine **SMAGGHE**
 delphine.smagghe@inserm.transfert.fr



This project has received funding from the European Union's Horizon 2020 Research and Innovation programme under Grant Agreement N° 825712.